AstraZeneca says its coronavirus vaccine triggers immune response among adults阿斯利康表示其新冠疫苗可以触发成人体内的免疫反应

LONDON — British pharmaceutical giant AstraZeneca on Monday said its potential Covid-19 vaccine has produced a similar immune response in older and younger adults.

伦敦-英国制药巨头阿斯利康在周一表示，其即将推出的Covid-19疫苗已经在老年和青壮年身体内产生类似的免疫反应。

AstraZeneca, which is developing its potential Covid-19 vaccine in collaboration with the University of Oxford, said adverse responses to the vaccine among the elderly were also found to be lower.

阿斯利康目前正在与牛津大学共同研发Covid-19疫苗。阿斯利康还发现，老年群体对疫苗所产生的副作用相对更低。

The World Health Organization has said that older people, in addition to people of all ages with preexisting medical conditions, appear to develop serious illness on contracting the coronavirus more often than others.

世界卫生组织表示，除了各个年龄段的、健康存在问题的人群之外，老年群体在感染到新冠病毒后似乎更容易出现严重的病症。

The announcement is likely to boost hopes of a Covid vaccine being developed before the end of the year.

这一消息让人们对今年年底推出新冠疫苗有了更大的希望。

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the COVID-19 disease severity is higher,” an AstraZeneca spokesman told CNBC via email.

阿斯利康发言人通过邮件向CNBC介绍到：“看到老人和青壮年体内产生类似的免疫应答让人倍受鼓舞，疫苗在老年体内所产生的反应原性更低，而老年群体在感染Covid-19后，其症状会更加严重。”

“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the Oxford-AstraZeneca vaccine.

发言人表示：“结果进一步证实了AZD1222（牛津-阿斯利康疫苗的学名）的安全性和免疫性。”

Shares of the company rose more than 2% on the news.

新闻推出后，公司股价上涨超过2%。

Drugmakers and research centers are scrambling to deliver a safe and effective vaccine in an attempt to bring an end to the coronavirus pandemic that has claimed over 1.15 million lives.

制药企业和研究机构都在争先恐后地推出安全有效的疫苗并期望通过疫苗控制新冠疫情。目前，新冠疫情已经夺走了115万人的生命。

Dozens of candidate vaccines are in clinical evaluation, according to the WHO, with some already conducting late-stage tests before seeking formal approval.

根据世界卫生组织介绍，目前已经有几十个候选疫苗正处于临床评估阶段，其中一些已经在获得正式批准前展开了大规模的测试。

The vaccine being developed by the University of Oxford and AstraZeneca is thought to be one of the frontrunners to secure regulatory approval.

由牛津大学和阿斯利康所研发的疫苗被认为是获得监管批准的领先疫苗之一。

AstraZeneca CEO Pascal Soirot has previously said the drugmaker’s vaccine would likely provide protection against contracting the coronavirus for about a year.

阿斯利康CE0 Pascal Soirot此前表示，制药公司推出的新冠疫苗可能会提供大约1年的免疫保护。

来源：CNBC，编辑：Susan